Probiotics inhibit cartilage damage and progression of osteoarthritis in mice

Supplementary Material

Antonia Sophocleous^{1,2}, Asim Azfer², Carmen Huesa³, Eleni Stylianou¹, Stuart H. Ralston²

¹Department of Life Sciences, School of Sciences, European University of Cyprus, Nicosia, Cyprus ²Rheumatology and Bone Diseases Unit, Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Cancer, Western General Hospital, University of Edinburgh, Edinburgh, UK ³Institute of Infection, Immunity & Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK Supplementary Table 1. MicroCT analysis of tibial subchondral bone from DMM-operated and unoperated knee joints of mice subjected to vehicle (n = 10) or probiotics (n = 11) treatment


	DMM knee		Un-operated knee	
mCT parameter	Vehicle	Probiotics	Vehicle	Probiotics
BV/TV (%)	29.4 ± 1.2	32.3 ± 0.8	27.9 ± 1.1	31.6 ± 0.6**
Tb.Th (μm)	56.9 ± 1.6	60.5 ± 1.0	53.9 ± 1.2	58.9 ± 0.9***
Tb.N (1/mm)	5.2 ± 0.1	5.3 ± 0.1	5.2 ± 0.1	54 ± 0.1
Tb.Sp (μm)	171.1 ± 3.9	168.0 ± 2.8	174.3 ± 3.4	169.1 ± 2.2
Tb.Pf (1/mm)	10.9 ± 1.0	9.3 ± 0.5	11.4 ± 0.7	9.0 ± 0.5*
Medial plate thickness (μm)	93.7 ± 3.9	110.4 ± 3.5**	91.0 ± 3.7	101.9 ± 1.9*
Lateral plate thickness (µm)	86.1 ± 2.3	86.8 ± 2.1	85.1 ± 4.3	98.5 ± 2.2*

mCT, microCT; BV/TV, trabecular bone volume; Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Pf, trabecular pattern factor. Values are mean \pm SEM. *p < 0.05; ** p < 0.01; ***p < 0.005 *vs.* vehicle.

Luminex® Cytokine Ν Vehicle Probiotics Region G-CSF 13 7-12 245.5 ± 40.8 323.7 ± 58.6 GM-CSF ND ND 15 _ IFNγ 19 ND ND IL-1 α 21 8-12 1313.7 ± 377.0 2418.2 ± 590.8 IL-1β 25 ND ND IL-2 26 ND ND IL-4 28 ND ND IL-5 13.4 ± 1.7 30 6-12 11.2 ± 1.4 IL-6 34 4-8 4.4 ± 0.9 6.4 ± 1.4 IL-7 36 ND ND IL-9 38 7-11 102.4 ± 15.3 102.3 ± 11.4 IL-10 43 10.5 ± 2.2 8-11 17.4 ± 2.5 IL-12 (p40) 45 5-9 9.1 ± 2.0 11.4 ± 2.3 IL12 (p70) 47 ND ND IL-13 52 7-11 40.5 ± 2.2 42.4 ± 2.2 IL-15 6-10 96.2 ± 20.7 54 112.2 ± 17.9 IL-17 7-12 56 16.4 ± 2.6 13.6 ± 1.4 IP-10 7-10 208.2 ± 26.9 211.9 ± 14.3 57 КС 7-11 123.9 ± 12.5 104.4 ± 12.9 61 MCP-1 62 7-12 38.5 ± 5.4 27.4 ± 4.2 MIP-1 α 64 7-11 82.1 ± 10.1 71.7 ± 6.5 MIP-1β 66 8-11 67.6 ± 5.6 57.3 ± 5.3 MIP-2 296.3 ± 33.3 73 8-11 257.1 ± 25.2 RANTES 75 55.6 ± 5.0 45.1 ± 6.5 8-12 77 TNFα ND ND

Supplementary Table 2. Cytokine and chemokine concentrations in vehicle- and probiotic-treated groups

G-CSF = Granulocyte colony stimulating factor; GM-CSF = granulocyte-macrophage colony stimulating factor; IL = Interleukin; KC = keratinocyte chemoattractant chemokine; MCP1 = monocyte chemoattractant protein 1; MIP = Macrophage inflammatory protein; RANTES = Regulated on activation normal T cell expressed and secreted; TNF = Tumour necrosis factor. Values are mean \pm SEM from 4-12 mice per group and the cytokine concentrations are in pg/ml. N = number of samples assayed; ND = not detectable. There was no significant difference between the groups considering multiple testing.



Supplementary Figure 1. Joint inflammation scores in the different treatment groups

Local inflammation in DMM-operated knee joints of mice subjected to the two different treatment groups, vehicle (n = 10) and probiotics (n = 11). **Panel A.** Pannus formation, defined as fibrous tissue/synovium/ inflammatory cell outgrowth spreading over the surface of the bone and/or cartilage at the joint margins; **Panel B.** Synovial hyperplasia, which includes the score for the maximum hyperplasia seen anywhere along the area assessed; **Panel C.** Sub-synovial inflammation, where the infiltration of inflammatory cells (neutrophils, macrophages and/or lymphocytes) is evaluated; **Panel D.** Sum inflammation score of A, B and C. The horizontal line indicates the mean value for each treatment group.